Zepbound label keeps separate maintenance doses for weight loss and sleep apnea

Zepbound's prescribing information was revised in August 2026 and continues to list two separate indications, each with a different minimum maintenance dose, according to the label ^[1]. The tirzepatide injection is indicated for weight reduction and long-term weight maintenance, and for moderate to severe obstructive sleep apnea (OSA) in adults with obesity ^[1].

The dose floors differ. For weight reduction and long-term maintenance, the labeled maintenance doses are 5 mg, 10 mg or 15 mg injected once weekly ^[1]. For moderate to severe OSA, the labeled maintenance doses are 10 mg or 15 mg once weekly ^[1]. The maximum recommended dosage for either use is 15 mg once weekly ^[1]. Both indications are for use alongside a reduced-calorie diet and increased physical activity ^[1].

The label separates the starting dose from maintenance. The recommended starting dosage is 2.5 mg once weekly for four weeks, and the label states that this dose is for initiation only and is not approved as a maintenance dosage ^[1]. After at least four weeks, the dose is raised in 2.5 mg increments until a maintenance dose is reached, with treatment response and tolerability considered when that dose is selected ^[1].

The two indications also describe different patient groups. The weight indication covers adults with obesity, or adults with overweight who also have at least one weight-related condition ^[1]. The OSA indication covers adults with obesity who have moderate to severe obstructive sleep apnea ^[1]. The label says Zepbound is not recommended for use with other tirzepatide-containing products or with any GLP-1 receptor agonist ^[1].

Safety language stays in place. Zepbound carries a boxed warning about thyroid C-cell tumors seen in rats, and the label says it is unknown whether the drug causes such tumors, including medullary thyroid carcinoma, in humans ^[1]. Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1]. The most common adverse reactions, reported in at least 5 percent of patients, include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss and gastroesophageal reflux disease ^[1]. The label says the drug may cause fetal harm and should be discontinued when pregnancy is recognized ^[1].

The label's recent major changes table lists a dosage and administration update in January 2026, a severe gastrointestinal adverse reactions change in February 2026, removal of a suicidal behavior and ideation warning in February 2026, a warning change on diabetic retinopathy complications in patients with type 2 diabetes in August 2026, and a January 2026 instruction never to share a Zepbound KwikPen between patients ^[1]. Initial U.S. approval was in 2022 ^[1].

Why it matters for patients

The practical effect of two dose floors is that the same drug has different labeled maintenance minimums depending on why it is prescribed. A maintenance dose of 5 mg once weekly is listed for weight reduction, but 5 mg is not among the labeled maintenance doses for obstructive sleep apnea ^[1]. Whether that split changes insurance coverage, prior authorization or what an individual prescriber selects has not been reported.

The label also makes clear that 2.5 mg once weekly is a starter dose only and is not an approved maintenance dosage ^[1]. The label gives 2.5 mg no maintenance role in either indication.

Pediatric use is another limit. The label states that safety and effectiveness have not been established in pediatric patients ^[1]. The label does not explain why the OSA maintenance floor is higher than the weight-reduction floor; that reasoning has not been disclosed.

What happens next

The label lists past revision dates rather than future ones. No further label changes, new indications or timelines have been disclosed ^[1].